{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T13:06:34Z","timestamp":1748264794651,"version":"3.37.3"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017540","name":"NHLBI Division of Intramural Research","doi-asserted-by":"publisher","award":["1R01HL163163"],"award-info":[{"award-number":["1R01HL163163"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There is a paucity of data on the initiation patterns of anticoagulants among older atrial fibrillation patients with and without chronic kidney disease (CKD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting and methods<\/jats:title><jats:p>We used the UK Clinical Practice Research Datalink (2010\u20132020) to conduct a retrospective cohort study to evaluate anticoagulant initiation patterns for older adults (\u226565 years) with CKD (N=18\u2009421) and without CKD (N=41\u2009901), categorised by severity of CKD: stages 3a, 3b and 4, and initiation dose by respective direct oral anticoagulant (DOAC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over the study period, warfarin initiations sharply declined and were replaced by DOACs regardless of CKD status or stage. By 2020, patients with CKD were modestly more likely (8.8% difference) to initiate apixaban compared with those without CKD (58.8% vs 50.0%; p&lt;0.01). Among patients with CKD, those with stages 3a and 3b CKD had higher apixaban initiations compared with stage 4 CKD (56.9% and 64.6% vs 52.9%, respectively; p&lt;0.01). Conversely, patients with stage 4 CKD were over three times more likely to initiate warfarin (14.7%) compared with those with stage 3a (2.6%) and 3b (4.0%) CKD (p&lt;0.01). Throughout the study period, there was a rise in the proportion of patients initiating the higher 10\u2009mg daily dose for apixaban, with an increase of 20.6% (from 64.3% in 2013 to 84.9% in 2020; p value for trend &lt;0.01) among patients without CKD, and 21.8% (53.1% to 74.9%; p&lt;0.01), 24.4% (18.8% to 43.2%; p&lt;0.01) and 18.5% (0.0% to 18.2%; p&lt;0.01) among patients with stages 3a, 3b and 4 CKD, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and relevance<\/jats:title><jats:p>Initiation of DOACs increased regardless of CKD status and stage, although with a reduced magnitude in severe CKD. Apixaban emerged as the preferred agent, with a secular trend towards the higher initiation dose in all subgroups. These findings illuminate evolving trends and priorities in anticoagulant preferences among patients with and without CKD.<\/jats:p><\/jats:sec>","DOI":"10.1136\/openhrt-2023-002515","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:10:13Z","timestamp":1706760613000},"page":"e002515","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Initiation patterns of anticoagulants for atrial fibrillation among older UK adults with and without chronic kidney disease, 2010\u20132020"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0594-9060","authenticated-orcid":false,"given":"Julia","family":"Liaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Liaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chintan","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"2024013120100492000_11.1.e002515.1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw079"},{"key":"2024013120100492000_11.1.e002515.2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03170509"},{"key":"2024013120100492000_11.1.e002515.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.020982"},{"key":"2024013120100492000_11.1.e002515.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)01107-4"},{"key":"2024013120100492000_11.1.e002515.5"},{"key":"2024013120100492000_11.1.e002515.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.816082"},{"key":"2024013120100492000_11.1.e002515.7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","author":"Freedman","year":"2016","journal-title":"The Lancet"},{"key":"2024013120100492000_11.1.e002515.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2024013120100492000_11.1.e002515.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.05.044"},{"key":"2024013120100492000_11.1.e002515.10","doi-asserted-by":"crossref","unstructured":"Huiart L , Ferdynus C , Renoux C , et al . Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. BMJ Open 2018;8:e018180. doi:10.1136\/bmjopen-2017-018180","DOI":"10.1136\/bmjopen-2017-018180"},{"key":"2024013120100492000_11.1.e002515.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.08.1623"},{"key":"2024013120100492000_11.1.e002515.12","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09260913"},{"key":"2024013120100492000_11.1.e002515.13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.phrs.2017.12.004","article-title":"Bleeding in advanced CKD patients on Antithrombotic medication\u2013a critical appraisal","volume":"129","author":"Burlacu","year":"2018","journal-title":"Pharmacol Res"},{"key":"2024013120100492000_11.1.e002515.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.011"},{"key":"2024013120100492000_11.1.e002515.15","unstructured":"National Institute for Health and Care Excellence . Atrial fibrillation: the management of atrial fibrillation (clinical guideline 180). 2021. Available: http:\/\/guidance.nice.org.uk\/CG180"},{"key":"2024013120100492000_11.1.e002515.16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European heart rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"EP Europace"},{"key":"2024013120100492000_11.1.e002515.17","doi-asserted-by":"crossref","first-page":"e636","DOI":"10.1016\/j.crvasa.2016.11.005","article-title":"ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. summary of the document prepared by the Czech society of cardiology","volume":"58","author":"\u010cih\u00e1k","year":"2016","journal-title":"Cor Vasa"},{"key":"2024013120100492000_11.1.e002515.18","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2024013120100492000_11.1.e002515.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"2024013120100492000_11.1.e002515.20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(97)04248-7","article-title":"The UK general practice research database","volume":"350","author":"Walley","year":"1997","journal-title":"The Lancet"},{"key":"2024013120100492000_11.1.e002515.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2102953\/SUPPL_FILE\/NEJMOA2102953_DISCLOSURES.PDF"},{"key":"2024013120100492000_11.1.e002515.22","unstructured":"A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis 2021."},{"key":"2024013120100492000_11.1.e002515.23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/jch.12095","article-title":"Prevalence of true therapeutic inertia in blood pressure control in an academic chronic kidney disease clinic","volume":"15","author":"Desai","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2024013120100492000_11.1.e002515.24","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.2337\/dc22-0224","article-title":"Trends in prescribing preferences for antidiabetic medications among patients with type 2 diabetes in the U.K","volume":"45","author":"Liaw","year":"2022","journal-title":"Diabetes Care"},{"key":"2024013120100492000_11.1.e002515.25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054990"},{"key":"2024013120100492000_11.1.e002515.26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu139"},{"key":"2024013120100492000_11.1.e002515.27","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.02.381"},{"key":"2024013120100492000_11.1.e002515.28","doi-asserted-by":"crossref","unstructured":"Iyer GS , Tesfaye H , Khan NF , et al . Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010-2020. JAMA Netw Open 2023;6:e234059. doi:10.1001\/jamanetworkopen.2023.4059","DOI":"10.1001\/jamanetworkopen.2023.4059"},{"key":"2024013120100492000_11.1.e002515.29","first-page":"899","article-title":"Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark","volume":"38","author":"Gadsb\u00f8ll","year":"2017","journal-title":"Eur Heart J"},{"key":"2024013120100492000_11.1.e002515.30","doi-asserted-by":"crossref","unstructured":"Yu AYX , Malo S , Svenson LW , et al . Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for Nonvalvular atrial fibrillation: A Canadian population-based study. J Am Heart Assoc 2017;6:e007129. doi:10.1161\/JAHA.117.007129","DOI":"10.1161\/JAHA.117.007129"},{"key":"2024013120100492000_11.1.e002515.31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40266-021-00859-1","article-title":"Trends in anticoagulant use at nursing home admission and variation by frailty and chronic kidney disease among older adults with atrial fibrillation","volume":"38","author":"Campitelli","year":"2021","journal-title":"Drugs Aging"},{"key":"2024013120100492000_11.1.e002515.32","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu225"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2023-002515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:10:25Z","timestamp":1706760625000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2023-002515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,31]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/openhrt-2023-002515"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2023-002515","relation":{},"ISSN":["2053-3624"],"issn-type":[{"type":"electronic","value":"2053-3624"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}